Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey

European Archives of Psychiatry and Clinical Neuroscience

Volumn 258, Issue 3, 2008, Pages 129-136

  Suvisaari, Jaana ^a,b   Perälä, Jonna ^a   Saarni, Samuli I ^a   Härkänen, Tommi ^a   Pirkola, Sami ^a,c   Joukamaa, Matti ^b,d   Koskinen, Seppo ^a   Lönnqvist, Jouko ^a,e   Reunanen, Antti ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Antipsychotic agents; Diabetes mellitus; Psychotic disorders; Type 2

Indexed keywords

ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOMEPROMAZINE; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; PERPHENAZINE; PROMAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; ZUCLOPENTHIXOL;

ADULT; AFFECTIVE PSYCHOSIS; AGE DISTRIBUTION; AGED; ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; FINLAND; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS;

AGE DISTRIBUTION; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; CHI-SQUARE DISTRIBUTION; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; FINLAND; HEALTH SURVEYS; HUMANS; INSULIN; MALE; MIDDLE AGED; MOOD DISORDERS; PREVALENCE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 43149125202     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00406-007-0762-y     Document Type: Article

References (50)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696
2. Aromaa A, Koskinen S (eds) (2004) Health and functional capacity in Finland. Baseline Results of the Health 2000 Health Examination Survey. Publications of the National Public Health Institute, B12. Available at http://www.ktl.fi/terveys2000/index.uk.html (accessed May 25, 2007)
3. Arranz B, Rosel P, Ramírez N, Dueñas R, Fernández P, Sanchez JM, Navarro MA, San L (2004) Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 65:1335-1342
4. Bellivier F (2005) Schizophrenia, antipsychotics and diabetes: genetic aspects. Eur Psychiatry 20:S335-S339
5. Brown S, Birtwistle J, Roe L, Thompson C (1999) The unhealthy lifestyle of people with schizophrenia. Psychol Med 29:697-701
6. Cassidy F, Ahearn E, Carroll BJ (1999) Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 156:1417-1420
7. Cohen D, Grobbee DE, Stolk RP, Gispen-De-Wied CC (2006) Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorder. Diabetes Care 29:786-791
8. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G (2004) Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 49:753-760
9. De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J (2006) Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemol Ment Health 2:14
10. De Hert MA, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J (2006) Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 83:87-93
11. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, Lehman A (2000) Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 26:903-912
12. Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults (2001) Executive summary of The Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-2497
13. Gianfrancesco F, Grogg A, Mahmoud R, Wang R-H, Meletiche D (2003) Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther 25:1150-1171
14. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D'Agostino RB, Stroup TS, Davis S, Lieberman JA (2005) A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 80:45-53
15. Gough SC, O'Donovan MC (2005) Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J Psychopharmacol 19(6 Suppl):47-55
16. Heistaro S (ed) (2005) Menetelmäraportti. Terveys 2000 -tutkimuksen toteutus, aineisto ja menetelmät (Implementation, data and methods of the Health 2000 Survey, in Finnish). Publications of the National Public Health Institute, B6
17. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC (2000) Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 157:975-981
18. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC (2005) Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents. Arch Gen Psychiatry 62:19-28
19. Hung C-F, Wu C-K, Lin P-Y (2005) Diabetes mellitus in patients with schizophrenia in Taiwan. Prog Neuro-Psychopharmacol Biol Psychiatry 29:523-527
20. Jin H, Meyer JM, Jeste DV (2004) Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 71:195-212
21. Kilbourne AM, Cornelius JR, Han X, Haas GL, Salloum I, Conigliaro J, Pincus HA (2005) General-medical conditions in older patients with serious mental illness. Am J Geriatr Psychiatry 13:250-254
22. Koponen H, Saari K, Savolainen M, Isohanni M (2002) Weight gain and glucose and lipid metabolism disturbances during antipsychotic medication. Eur Arch Psychiatry Clin Neurosci 252:294-298
23. Kuehn BM (2005) FDA warns antipsychotic drugs may be risky for elderly. JAMA 293:2462
24. Kupfer DJ (2005) The increasing medical burden in bipolar disorder. JAMA 293:2528-2530
25. Lamberti JS, Crilly JF, Maharaj K, Olson D, Wiener K, Dvorin S, Costea GO, Bushey MP, Dietz MB (2004) Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. J Clin Psychiatry 65:702-706
26. Lazarus R, Sparrow D, Weiss ST (1997) Handgrip strength and insulin levels: cross-sectional and prospective associations in the Normative Aging Study. Metabolism 46:1266-1269
27. Lee J (1981) Covariance adjustment of rates based on the multiple logistic regression model. J Chronic Dis 34:415-426
28. Leslie DL, Rosenheck RA (2004) Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 161:1709-1711
29. Lindenmayer J-P, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 160:290-296
30. Montonen J, Knekt P, Harkanen T, Jarvinen R, Heliovaara M, Aromaa A, Reunanen A (2005) Dietary patterns and the incidence of type 2 diabetes. Am J Epidemiol 161:219-227
31. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio P (1996) Diabetes mellitus in schizophrenic patients. Compr Psychiatry 37:68-73
32. Nasrallah H, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA (2006) Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 86:15-22
33. National Agency for Medicines and Social Insurance Institution (2005) Finnish Statistics on Medicines 2004. Edita Prima Oy, Helsinki
34. National Agency for Medicines and Social Insurance Institution (2001) Finnish Statistics on Medicines 2000. Edita Oy, Helsinki
35. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G (2002) Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59:337-345
36. Patja K, Jousilahti P, Hu G, Valle T, Qiao Q, Tuomilehto J (2005) Effects of smoking, obesity and physical activity on the risk of type 2 diabetes in middle-aged Finnish men and women. J Intern Med 258:356-362
37. Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S, Partonen T, Tuulio-Henriksson A, Hintikka J, Kieseppä T, Härkänen T, Koskinen S, Lönnqvist J (2007) Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 64:19-28
38. Philippe A, Vaiva G, Casadebaig F (2005) Data on diabetes from the French cohort study in schizophrenia. Eur Psychiatry 20:S340-S344
39. Pierce M, Keen H, Bradley C (1995) Risk of diabetes in offspring of parents with non-insulin-dependent diabetes. Diabet Med 12:6-13
40. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV (2002) Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 70:19-26
41. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Diabetes Care 20:1183-1197
42. Research Triangle Institute (2004) SUDAAN Language Manual, Release 9.0. Research Triangle Park, NC: Research Triangle Institute
43. Ryan MCM, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160:284-289
44. Stewart R, Liolitsa D (1999) Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 16:93-112
45. Stumvoll M, Goldstein BJ, van Haeften TW (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365:1333-1346
46. Subramaniam M, Chong S-A, Pek E (2003) Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 48:345-347
47. Susce MT, Villanueva N, Diaz FJ, de Leon J (2005) Obesity and associated complication in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry 66:167-173
48. van Winkel R, De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J (2006) Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: Evaluation of incidence and screening methods. J Clin Psychiatry 67:1493-1500
49. Weiss AP, Henderson DC, Weiburg JB, Goff DC, Meigs JB, Cagliero E, Grant RW (2006) Treatment of cardiac risk factors among patients with schizophrenia and diabetes. Psychiatr Serv 57:1145-1152
50. World Health Organization Expert Committee (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation, part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization